Association Between Psoriasis and Sexual and Erectile Dysfunction in Epidemiologic Studies

Molina-Leyva, Alejandro; Salvador‐Rodríguez, Luis; Martínez-López, Antonio; Ruiz‐Carrascosa, J.C.; Arias‐Santiago, Salvador

doi:10.1001/jamadermatol.2018.3442

Cited by 36 publications

(38 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the first population-based study to directly investigate the incidence of ED in men with PsA. Previous studies found an increased risk of ED in patients with psoriasis who also had PsA (9,10,12). The findings of this study are consistent with previous studies, although the increased risk in this study did not reach statistical significance due to the low numbers of ED cases (24 and 18 cases in the PsA and comparator cohorts, respectively).…”

Section: Discussionsupporting

confidence: 78%

“…Psoriatic arthritis (PsA) is a systemic inflammatory disease which, in addition to chronic inflammatory joint and entheseal symptoms, confers an increased risk of comorbidities, including both cardiovascular disease (1)(2)(3)(4)(5)(6)(7)(8) and sexual dysfunction (9)(10)(11)(12). PsA is associated with increased mortality, with cardiovascular disease representing the leading cause of death (13).…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, PsA patients have a higher risk of psychiatric comorbidities such as anxiety, depression; and the psychological impact of psoriasis and PsA may be associated with sexual dysfunction (35). Previous studies have shown that PsA (9,10,12) and psoriatic disease activity (36)(37)(38) are both risk factors for ED in men with psoriasis, a population known to have an increased risk of sexual dysfunction. However, unlike sexual dysfunction, and despite this implied association, the incidence of ED in men with PsA has not been previously analyzed in a population-based cohort and has been minimally analyzed by other methods (39).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Erectile Dysfunction in Men With Psoriatic Arthritis: A Population-based Cohort Study

et al. 2020

View full text Add to dashboard Cite

Objective To define the incidence of erectile dysfunction (ED) in a population-based cohort of men with psoriatic arthritis (PsA). Methods Data pertaining to demographics, ED, and potential confounding diagnosis were extracted from a comprehensive medical record system for a population-based cohort of men with PsA and an age-matched male comparator cohort. Cumulative incidence of ED adjusted for competing risk of death was compared between the two cohorts. Results There were 128 age-matched pairs of men with PsA and without PsA in the described cohorts. At baseline there was a 7% prevalence of ED in men with PsA prior to diagnosis compared to a 3% prevalence of ED in the comparator cohort (p=0.16). After PsA diagnosis / index date, diagnosis with PsA was associated with an increased risk of ED (age-adjusted HR 1.45, 95%CI: 0.79-2.68), but this association did not reach statistical significance. This was based on 24 cases of ED in the men with PsA and 18 cases within the comparator cohort. No confounding factors or ED treatment strategies differed significantly between men with PsA and ED and comparators with ED. Conclusion Men with PsA may have an increased risk of ED, which was detected, but likely underpowered in this study. Whether this difference is secondary to higher prevalence of traditional risk factors of ED in men with PsA compared to general population will require further study.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Erectile Dysfunction in Men With Psoriatic Arthritis: A Population-based Cohort Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…reported erectile dysfunction in a 39-year-old patient with psoriasis after initiation of acitretin therapy. On a follow-up visit, the patient reported an inability to reach and maintain a penile erection sufficient enough to perform a sexual act, beginning from about 45 days after the initiation of therapy [13]. The literature provides two more case reports on the development of impotence associated with the use of etretinate.…”

Section: Discussionmentioning

confidence: 99%

Untitled

2020

Our Dermatol Online

View full text Add to dashboard Cite

Acitretin is a second-generation oral retinoid used by dermatologists for the treatment of dermatological disorders such as psoriasis, pityriasis rubra pilaris, and lichen planus [1]. Acitretin may cause some common side effects such as dry skin and mucosa, hyperlipidemia, muscle and joint pain, and hepatitis [2]. Erectile dysfunction is defined as the inability to achieve and maintain a penile erection adequate for satisfactory sexual intercourse. Erectile dysfunction may be due to various reasons, including psychogenic and organic factors, endocrine disorders, and drug use [3]. Data on the effect of acitretin on sexual function is limited. The literature provides no studies that would investigate whether acitretin causes erectile dysfunction in humans. Therefore, in this study, we aimed at investigating whether patients taking acitretin develop erectile dysfunction. MATERIALS AND METHODS The study included 40 male patients who presented to the Dermatology Polyclinic of Okmeydanı Training and Research Hospital between October 2014 and April 2016 and started treatment with acitretin for various dermatological disorders. Exclusion criteria included psychogenic and psychiatric disorders, diabetes mellitus, ABSTRACT Background: Acitretin is a second-generation oral retinoid compound used as a treatment option for various dermatological disorders. The effects of the drug on erectile function have not been fully determined yet. We aimed at investigating whether patients taking acitretin develop erectile dysfunction (ED). Materials and Methods: The study included 40 male patients who presented to the Dermatology Polyclinic of Okmeydanı Training and Research Hospital between October 2014 and April 2016 and started treatment with acitretin. Exclusion criteria included psychogenic and psychiatric disorders, neurological disorders such as multiple sclerosis, diabetes mellitus and endocrine disorders, arteriogenic and venous disorders, alcohol and tobacco use, penile disorders, obesity, a history of drug use, a score of above 10 points in the Beck Depression Inventory (BDI), hyperlipidemia, and an age above 65 years. Having obtained the informed consent, the patients were asked to complete the International Index of Erectile Function (IIEF) questionnaire before and after three months of therapy. The patients were evaluated by calculating their scores and a statistical analysis was performed. Results: A total of 40 patients were included in the study. A comparison of the IIEF scores before and after three months of therapy revealed that the scores were significantly lower after three months of therapy (P < 0.0001). ED was diagnosed in 30 patients (75%) at the beginning of therapy and in 35 patients (87.5%) after three months of therapy. A comparison of baseline and 3-month IIEF grades revealed that the number of patients in the second group was significantly greater after three months of therapy with the drug (P = 0.001). When the percentage of patients with erectile dysfunction at the baseline and after three months of ther...

show abstract

“…Rates of anxiety, depression and even suicide are increased in these patients [29]. Psoriasis can also influence the interpersonal and sexual health of people with psoriasis [30]. Psoriasis therefore impacts on physical, emotional, and social patient's life [20].…”

Section: Psoriasismentioning

confidence: 99%

Quality of Life in Patients with Skin Disease and Their Cohabitants

Montero‐Vílchez¹,

Sánchez‐Díaz²,

Martínez-López³

et al. 2022

Self Cite

View full text Add to dashboard Cite

Health evaluation implies assess multidimensional aspects of a person’s development, such as physical, social, psychological, and emotional features. It is important to consider all these factors to apply a needs-oriented each patient approach. Chronic skin diseases have a great impact on quality of life, even more than other chronic conditions. For example, hidradenitis suppurativa is estimated to impair quality of life more than cardiovascular disease, lung disease or endocrine diseases. Multiple tools have been developed to measure health-related quality of life in patient, being the Dermatology Life Quality Index (DLQI) the most used. Psoriasis, hidradenitis suppurativa, acne, atopic dermatitis and hair disorders are those with the greatest impact on patients’ quality of life. Moreover, chronic skin conditions impair not only patients’ quality of life, but also cohabitants. Nevertheless, there is scarce information regarding the impact on their cohabitants. So, the objective of this chapter is to review the literature to assess the psychological and social effects of dermatological conditions both on patients and cohabitants.

show abstract

Association Between Psoriasis and Sexual and Erectile Dysfunction in Epidemiologic Studies

Cited by 36 publications

References 51 publications

Erectile Dysfunction in Men With Psoriatic Arthritis: A Population-based Cohort Study

Erectile Dysfunction in Men With Psoriatic Arthritis: A Population-based Cohort Study

Untitled

Quality of Life in Patients with Skin Disease and Their Cohabitants

Contact Info

Product

Resources

About